PITOCIN Drug Patent Profile

Which patents cover Pitocin, and what generic alternatives are available?

Pitocin is a drug marketed by Ph Health and is included in one NDA.

The generic ingredient in PITOCIN is oxytocin. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the oxytocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pitocin

A generic version of PITOCIN was approved as oxytocin by HIKMA on January 10^th, 2007.

Summary for PITOCIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	107
Drug Prices:	Drug price information for PITOCIN
What excipients (inactive ingredients) are in PITOCIN?	PITOCIN excipients list
DailyMed Link:	PITOCIN at DailyMed

See drug prices for PITOCIN

Recent Clinical Trials for PITOCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Icahn School of Medicine at Mount Sinai	PHASE3
Bronx Care Health System	PHASE3
University of Maryland, Baltimore	Early Phase 1

See all PITOCIN clinical trials

Pharmacology for PITOCIN

Drug Class	Oxytocic
Physiological Effect	Increased Uterine Smooth Muscle Contraction or Tone

US Patents and Regulatory Information for PITOCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	PITOCIN	oxytocin	INJECTABLE;INJECTION	018261-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Ph Health	PITOCIN	oxytocin	INJECTABLE;INJECTION	018261-002	Jul 27, 2007	AP	RX	Yes	No
Ph Health	PITOCIN	oxytocin	INJECTABLE;INJECTION	018261-003	Sep 5, 2012		RX	Yes	No

PITOCIN Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for PITOCIN?

PITOCIN (oxytocin) is a synthetic hormone primarily used to induce or augment labor, manage postpartum hemorrhage, and facilitate breastfeeding. Its market landscape has remained relatively stable with specific drivers influencing demand, supply, and regulation.

Demand Drivers

• Obstetric Indications: The primary use of PITOCIN is in obstetrics, with a global increase in birth rates marginally increasing pharmaceutical interventions. The World Health Organization reports approximately 385,000 maternal deaths annually, many associated with postpartum hemorrhage, which PITOCIN effectively manages (WHO, 2021).

• Global Birth Rates: The UN estimates 140 million births annually; demand for labor induction and postpartum hemorrhage management sustains steady medication needs.

• Healthcare Infrastructure: Developed countries exhibit high utilization rates due to standardized obstetric protocols. Emerging markets show increasing adoption driven by expanding healthcare access and evolving obstetric practices.

• Regulatory and Approval Environment: Several jurisdictions restrict or regulate oxytocin use, impacting market penetration. For example, certain countries impose stringent controls to prevent misuse, which can influence supply and pricing.

Supply Chain Dynamics

• Manufacturers: Major pharmaceutical firms such as Pfizer and Ferring Pharmaceuticals dominate in high-income markets, with generic producers supplying lower-cost options in emerging markets.

• Supply Constraints: Limited raw material availability and stringent manufacturing standards influence production capacity. Regulatory compliance adds to costs and can hinder new entrants.

• Pricing and Reimbursement: Strong reimbursement policies in developed markets support consistent demand, while price sensitivity in lower-income regions influences the proliferation of generics.

Competitive Landscape

• Generic Competition: The patent expiration of branded formulations has increased generic availability, reducing prices. Price erosion has intensified, especially in regions with high generic penetration.

• Product Substitutes: Alternatives like misoprostol are sometimes preferred for labor induction, especially where oxytocin availability or regulation is restrictive. This competition influences core market revenue for PITOCIN.

• Biologics and New Delivery Modalities: No biologic substitutes exist; however, innovations such as controlled-release formulations are under exploration.

What Is the Financial Trajectory for PITOCIN?

Revenue and Market Size

• Global Market Value: The global uterotonic market, encompassing PITOCIN, was valued at around USD 1.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2027 (Research and Markets, 2022).

• Regional Revenue Breakdown: North America holds roughly 45% of the market, driven by high obstetric procedure volumes and reimbursement. Europe accounts for approximately 25%, with the rest distributed across Asia-Pacific, Latin America, and Africa.

Key Revenue Factors

• Pricing Trends: Prices declined sharply after patent expirations, particularly in the early 2010s, with generics pricing 50-70% lower than branded products.

• Effect of Regulation: Stringent settings in certain countries limit sales volume growth, while relaxed norms in emerging markets bolster volume.

• Volume vs. Price: The market's growth relies more on volume increases in emerging regions than on price changes in developed economies.

Profit Margins

• Branded vs. Generic: Gross margins on branded PITOCIN can reach 70-80%, whereas generics average 30-50% due to competitive pricing.

• Manufacturing Costs: Standardized manufacturing, along with regulation compliance costs, influence overall margins. Potent demand in high-income markets sustains higher margins.

Investment and R&D Outlook

• Innovation Scarcity: Limited innovation efforts exist, which constrains R&D expenditure growth. Companies primarily focus on manufacturing efficiencies and expanding access.

• Potential Markets: Countries with increasing healthcare investments represent opportunities for product localization and expanding distribution.

How Do Regulatory and Policy Factors Impact Market and Financial Outlook?

• Regulatory Constraints: Stricter control over hormone distribution in certain countries restricts market access for unapproved or counterfeit products.

• Quality Control: Emphasis on Good Manufacturing Practices (GMP) raises operational costs but enhances product credibility.

• Reimbursement Policies: Favorable coverage in high-income countries sustains revenue, while cost sensitivity in low-income markets challenges profitability.

• Global Health Initiatives: Programs aimed at reducing maternal mortality may promote increased PITOCIN use through funding and policy advocacy.

Key Takeaways

• The PITOCIN market remains stable with predictable demand driven by obstetric needs.

• Patent expirations and the proliferation of generics have driven prices downward, impacting margins but expanding access in emerging markets.

• Regulatory environments significantly influence supply, pricing, and market penetration.

• The global market is expected to grow modestly at 4% CAGR through 2027, with high-income regions leading revenue generation.

• Innovation in delivery methods or alternative therapies remains limited, emphasizing manufacturing efficiency and access expansion.

FAQs

1. What are the primary drivers of demand for PITOCIN?
   Obstetric use for labor induction and postpartum hemorrhage management, with steady global birth rates and healthcare infrastructure supporting demand.

2. How do patent expirations influence market revenues?
   They lead to increased generic competition, reducing prices and margins but broadening access, especially in lower-income regions.

3. What competitive factors threaten PITOCIN market stability?
   Competition from alternative drugs like misoprostol and potential regulatory restrictions.

4. What is the projected growth rate for the PITOCIN market?
   Approximately 4% CAGR through 2027.

5. Are there emerging innovations in PITOCIN delivery?
   Limited; focus remains on manufacturing efficiency and expanding access rather than novel formulations.

---

References

[1] World Health Organization (WHO). Maternal Mortality. 2021.
[2] Research and Markets. Global Uterotonic Market Forecast. 2022.